SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm

Core Viewpoint - Kaskela Law LLC is investigating Sage Therapeutics, Inc. on behalf of long-term investors due to a securities fraud complaint filed against the company [1][2]. Summary by Relevant Sections Allegations of Misconduct - The complaint alleges that during the Class Period (April 12, 2021 to July 23, 2024), Sage and its senior executives concealed significant risks and adverse information regarding the development of three key pharmaceuticals: zuranolone (SAGE-217/BIIB125), SAGE-718, and SAGE-324 [3]. FDA Findings and Impact - By the end of the Class Period, it was revealed that the FDA denied approval for zuranolone for treating major depressive disorder (MDD) due to its lack of long-term efficacy and its performance being no better than a placebo. The FDA's guidance from 2018 indicated a need for a more effective treatment for MDD [4]. - The FDA approved zuranolone for postpartum depression (PPD) but noted an increased incidence of suicidal ideation and behavior in MDD patients, which was not observed in PPD patients [4]. - Sage also abandoned the development of SAGE-718 and SAGE-324 due to negative clinical trial results, leading to Biogen terminating its collaboration and licensing agreement for SAGE-324 [4]. Investigation Focus - The investigation aims to determine if Sage's board of directors violated securities laws or breached fiduciary duties related to the alleged misconduct [5].